US FDA’s Foreign Data Policy Faces Its Greatest Test From Chinese PD-1/L1 Inhibitors
Executive Summary
The swift rise of China’s oncology R&D has put at least four novel applications before FDA with pivotal data generated only in China.
You may also be interested in...
US FDA Denies Petition Seeking Freeze On Russian Companies’ Regulatory Activities
Agency tells former OOPD director Tim Coté it doesn't have the authority to consider sponsor’s country of origin when determining whether to act on applications. Despite the denial of petition, FDA continues to support Ukraine.
US FDA Denies Petition Seeking Freeze On Russian Companies’ Regulatory Activities
The agency tells former OOPD Director Tim Coté that it does not have the authority to consider the sponsor’s country of origin when determining whether to act on an application.
EQRx Price Disruptor Business Model Faces The Costly Reality Of FDA Drug Development Standards
Start-up firm, with two Chinese-developed drugs for lung cancer in late-stage development, may be particularly vulnerable to the US Food and Drug Administration’s recently stated opposition to the Chinese-only research supporting Eli Lilly’s sintilimab.